Patanjali, the Ayurveda company founded by Yoga guru Baba Ramdev, on Tuesday, said that the clinical trials that it had conducted for Covid-19 treatment have been registered with Clinical Trials Registry of India.
Acharya Balkrishna, Chairman, tweeted that Patanjali has cleared the communication gap with the government and the standard protocols were fulfilled for the randomised placebo-controlled clinical trials, and has submitted this information to Ayush Ministry. He also said that the current government promotes Ayurveda.
The reply came after the Ministry of Ayush earlier said that it is not aware of the facts of the claims and details of the stated scientific study by the company.
“Patanjali Ayurved Ltd has been asked to provide at the earliest details of the name and composition of the medicines being claimed for Covid treatment; site(s)/hospital(s) where the research study was conducted for Covid-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration, and results data of the study (ies),” it said.
It had also asked Patanjali to stop advertising or publicising its claims till the issue is duly examined. The Ministry has also requested the concerned State licensing authority of Uttarakhand to provide copies of the licence and product approval details of the Ayurvedic medicines that are being used for the treatment of Covid.
On Tuesday, the company launched Ayurvedic medicines ‘Divya Coronil’ and ‘Divya Swasari Vati’ for Covid-19, claiming that it was a cure. At a press conference, the company shared results of a randomised double-blind clinical trial conducted by Patanjali Research Institute, in collaboration with the National Institute of Medical Sciences (NIMS University), on 100 Covid-19 patients.
“In the group that was given the drugs, 69 per cent tested negative for Covid-19 on the third day. By the seventh day, all patients in the drug arm recovered. There were no deaths observed in the study,” said Ramdev.
Patanjali has yet not published the data from its study in any journal. “The scientific prospects of these Ayurvedic medicines are currently under the peer review process for their publication in esteemed journals of international repute,” the company states.
A letter from the Editor
Dear Readers,
The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.
Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.
In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.
We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.
But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.
I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.
A little help from you can make a huge difference to the cause of quality journalism!
Support Quality Journalism